EGFR and glioblastoma: In addition, they featured frequencies of TP53 and ATRX mutations (74.4%; 12.8%) significantly higher than IDH-wt (27%; 4.6%; P < 0.0001; P = 0.0301) and lower than IDH-mutant GBMs (96.2%; 76.2%; P = 0.0139; P < 0.0001), and frequency of EGFR amplification (17.9%) significantly lower than IDH-wt (46.3%; P = 0.0006) and higher than IDH-mutant GBM (0%; P = 0.0001) (Table 2).